Proellex®, is an orally active, small molecule, selective blocker of the progesterone receptor that we developed for three indications: pre-surgical short course treatment of anemia associated with uterine fibroids, chronic treatment of uterine fibroids, and endometriosis.
On August 3, 2009, Repros Therapeutics announced it voluntarily suspended dosing of all patients in its clinical trials of Proellex. On August 4, 2009, the United States Food and Drug Administration (FDA) informed Repros that the Company’s Investigational New Drug Applications (INDs) for Proellex had been placed on clinical hold for safety reasons.